Abstract 182P
Background
Large desmoplasia, unique tumor microbiome and the immunosuppressive tumor microenvironment has been observed in pancreatic ductal adenocarcinoma (PDAC). Branched polypeptides (BP) are complex engineered structures acting as immunomodulators to control tumor growth. Immune checkpoint inhibitors (ICI) induce antitumor responses, while inhibition of focal adhesion kinase (FAK) reduces fibrosis and boosts immune surveillance. This study aimed to evaluate the in vivo antitumor immune effects and microbiota diversity induced by BP conjugated with PDAC-associated peptide antigens MHCI/II ([BP-MHCI/II]) in combination with an ICI and a FAK inhibitor (FAKi).
Methods
BP were conjugated with MHCI and MHCII-PDAC peptides. To assess the impact of the nanoconjugate on orthotopic PDAC tumor growth, KPC cells were implanted in the pancreas of mice. On day 7, mice were immunized with two doses of either PBS, free antigens/adjuvants (MHCI/MHCII antigens + Toll-like receptor ligands), or [BP-MHCI/II] mixed with adjuvants and combined with ICI and FAKi. Mice weight was monitored regularly. On day 20, PDAC tumors were collected. Functional markers of tumor-infiltrating immune cells were quantified by FACS, and gut and tumor-associated microbiota diversity was analyzed through 16S metagenomic sequencing, followed by QIIME2.11 bioinformatic tools.
Results
[BP-MHCI/II] exhibited a mean diameter of 40 nm and a zeta potential (ZP) of -25 mV, with MHCI and MHCII peptide loading efficiencies of 20% and 13%, respectively. Tumor reduction was more pronounced in mice treated with [BP-MHCI/II] in combination with ICI and FAKi, compared to PBS. The combination treatment modulated tumor-infiltrating immune cells promoting antitumor immunity. Also, gut and tumor microbiota composition and diversity varied among treatments.
Conclusions
The combination of [BP-MHCI/II] with ICI and FAKi represents a promising strategy to overcome tumor growth, to modulate immune cells in tumor microenvironment and microbiota composition in PDAC.
Legal entity responsible for the study
The author.
Funding
Fundação para a Ciência e Tecnologia (FCT).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
Resources:
Abstract
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract